BRPI0510231A - composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo - Google Patents

composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo

Info

Publication number
BRPI0510231A
BRPI0510231A BRPI0510231-6A BRPI0510231A BRPI0510231A BR PI0510231 A BRPI0510231 A BR PI0510231A BR PI0510231 A BRPI0510231 A BR PI0510231A BR PI0510231 A BRPI0510231 A BR PI0510231A
Authority
BR
Brazil
Prior art keywords
preparing
snac
water
cosolvate
snac form
Prior art date
Application number
BRPI0510231-6A
Other languages
English (en)
Inventor
Halina Levchik
Shingai Majuru
Brahma Singh
Jamila Harris
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of BRPI0510231A publication Critical patent/BRPI0510231A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOSTO, POLIMORFO CRISTALINO, COSSOLVATO EM METANOL E áGUA, COSSOLVATO EM METANOL-áGUA, COSSOLVATO EM ETANOL, áGUA, COMPOSIçãO FARMACêUTICA, MéTODO PARA ADMINISTRAR UM AGENTE ATIVO, MéTODO PARA PREPARAR A FORMA I DO SNAC, MéTODO PARA PREPARAR A FORMA II DE SNAC, MéTODO PARA PREPARAR A FORMA III DE SNAC, MéTODO PARA PREPARAR A FORMA IV DE SNAC, MéTODO PARA PREPARAR A FORMA V DE SNAC, MéTODO PARA PREPARAR A FORMA VI DE SNAC, COMPOSIçãO FARMACêUTICA E MéTODO PARA PREPARAR SNAC AMORFO. A presente invenção refere-se a formas polirmórficas cristalinas de N- ¢8- (hidroxibenzoil) amino! caprilato monossódico ("SNAC"), incluindo dois hidratos, um solvato em metanol, e um solvato em etanol, de SNAC. Mais especificamente, a presente invenção provê seis formas polimórficas de SNAC (daqui por diante Formas I-VI) A presente invenção também provê uma forma amorfa de SNAC.
BRPI0510231-6A 2004-05-06 2005-05-06 composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo BRPI0510231A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56947604P 2004-05-06 2004-05-06
US61941804P 2004-10-15 2004-10-15
PCT/US2005/016126 WO2005107462A2 (en) 2004-05-06 2005-05-06 Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate

Publications (1)

Publication Number Publication Date
BRPI0510231A true BRPI0510231A (pt) 2007-10-30

Family

ID=35320672

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510231-6A BRPI0510231A (pt) 2004-05-06 2005-05-06 composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo

Country Status (14)

Country Link
US (6) US8636996B2 (pt)
EP (3) EP3572086B1 (pt)
JP (1) JP4903690B2 (pt)
CN (6) CN102040535B (pt)
AU (1) AU2005240213B8 (pt)
BR (1) BRPI0510231A (pt)
CA (2) CA2563681C (pt)
EA (1) EA013518B1 (pt)
ES (3) ES2729825T3 (pt)
IL (1) IL178677A (pt)
MX (1) MXPA06012842A (pt)
NZ (1) NZ550890A (pt)
SG (1) SG153039A1 (pt)
WO (1) WO2005107462A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005995A2 (en) 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
JP5475443B2 (ja) * 2006-06-28 2014-04-16 エミスフェアー・テクノロジーズ・インク 硝酸ガリウム製剤
WO2008014232A2 (en) * 2006-07-24 2008-01-31 Emisphere Technologies, Inc. Pharmaceutical formulations for the treatment of alzheimer's disease
BRPI0716539A2 (pt) 2006-09-07 2016-11-01 Emisphere Tech Inc métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste
PL2215047T3 (pl) * 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
US20110039930A1 (en) 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
WO2011106378A2 (en) * 2010-02-24 2011-09-01 Emisphere Technologies, Inc. Oral b12 therapy
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
PL2696687T3 (pl) 2011-04-12 2017-06-30 Novo Nordisk A/S Pochodne podwójnie acylowanej GLP-1
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
PT2827845T (pt) 2012-03-22 2019-03-29 Novo Nordisk As Composições compreendendo um agente de entrega e sua preparação
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
PL2897620T3 (pl) * 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
US10954824B2 (en) 2016-12-19 2021-03-23 General Electric Company Systems and methods for controlling drum levels using flow
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
EP4159712B1 (en) * 2020-05-29 2025-03-19 Sciwind Biosciences Co., Ltd. N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof
JP7638693B2 (ja) * 2020-12-15 2025-03-04 大阪瓦斯株式会社 ヒドロキシアルカン酸結晶の製造方法及びヒドロキシアルカン酸の結晶多形体
CA3223247A1 (en) 2021-07-16 2023-01-19 Thomas Kvistgaard Vilhelmsen Sodium n-(8-(2- hydroxybenzoyl)amino)caprylate polymorphic form a
CN115108936A (zh) * 2022-07-29 2022-09-27 成都普康唯新生物科技有限公司 无水体系制备8-(2-羟基苯甲酰胺基)辛酸钠无水晶型的方法
IT202300028002A1 (it) 2023-12-27 2025-06-27 Olon Spa Processo per la preparazione di salcaprozato sodico nella forma cristallina i.
CN117466765B (zh) * 2023-12-27 2024-03-15 成都道合尔医药技术有限公司 8-(2-羟基苯甲酰胺基)辛酸钠及其合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421685A (en) 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US5534488A (en) 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) * 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
ES2235854T3 (es) * 1999-04-05 2005-07-16 Emisphere Technologies, Inc. Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos.
WO2002015959A2 (en) * 2000-08-18 2002-02-28 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US7138546B2 (en) * 2000-08-18 2006-11-21 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
NZ527157A (en) * 2001-03-01 2005-04-29 Emisphere Tech Inc Compositions for delivering bisphosphonates
JP2002332231A (ja) * 2001-03-06 2002-11-22 Jiro Takada γ−ＣＥＨＣ送達剤

Also Published As

Publication number Publication date
IL178677A (en) 2012-03-29
US10188621B2 (en) 2019-01-29
US9321719B2 (en) 2016-04-26
US10744105B2 (en) 2020-08-18
US20170326087A1 (en) 2017-11-16
JP2007536275A (ja) 2007-12-13
CN102001963B (zh) 2014-04-16
CN102040535B (zh) 2012-10-17
HK1157318A1 (en) 2012-06-29
CN102001962A (zh) 2011-04-06
EA013518B1 (ru) 2010-06-30
CN102040537A (zh) 2011-05-04
EP1773351A2 (en) 2007-04-18
CN102040538A (zh) 2011-05-04
CA2897225A1 (en) 2005-11-17
ES2729825T3 (es) 2019-11-06
WO2005107462A3 (en) 2006-05-04
JP4903690B2 (ja) 2012-03-28
US20210177792A1 (en) 2021-06-17
AU2005240213B2 (en) 2011-09-22
IL178677A0 (en) 2007-02-11
AU2005240213B8 (en) 2011-10-20
AU2005240213A1 (en) 2005-11-17
SG153039A1 (en) 2009-06-29
US20140187813A1 (en) 2014-07-03
EP1773351A4 (en) 2008-04-30
EP3572086A1 (en) 2019-11-27
HK1153731A1 (en) 2012-04-05
HK1153730A1 (en) 2012-06-22
WO2005107462A2 (en) 2005-11-17
MXPA06012842A (es) 2007-02-15
EP3572086B1 (en) 2021-05-05
EP1773351B1 (en) 2019-04-24
CN102001962B (zh) 2013-04-03
EP3058944A1 (en) 2016-08-24
HK1157737A1 (en) 2012-07-06
AU2005240213A8 (en) 2011-10-20
CA2897225C (en) 2017-12-05
US11395809B2 (en) 2022-07-26
ES2879880T3 (es) 2021-11-23
US9750710B2 (en) 2017-09-05
ES2739500T3 (es) 2020-01-31
US20190343786A1 (en) 2019-11-14
CN102040535A (zh) 2011-05-04
US20090143330A1 (en) 2009-06-04
NZ550890A (en) 2009-10-30
HK1157317A1 (en) 2012-06-29
CN102001963A (zh) 2011-04-06
CN102040536B (zh) 2013-06-19
CA2563681C (en) 2015-11-03
CN102040536A (zh) 2011-05-04
EA200602066A1 (ru) 2007-06-29
US8636996B2 (en) 2014-01-28
CA2563681A1 (en) 2005-11-17
US20160184251A1 (en) 2016-06-30
CN102040538B (zh) 2013-02-13
EP3058944B1 (en) 2019-06-19

Similar Documents

Publication Publication Date Title
BRPI0510231A (pt) composto, polimorfo cristalino, cossolvato em metanol e água, cossolvato em metanol-água, cossolvato em etanol-água, composição farmacêutica, método para administrar um agente ativo, método para preparar a forma i do snac, método para preparar a forma ii de snac, método para preparar a forma iii de snac, método para preparar a forma iv de snac, método para preparar a forma v de snac, método para preparar a forma vi de snac, composição farmacêutica e método para preparar snac amorfo
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
BRPI0606318A2 (pt) composto, composição, e, uso de um composto
AR052404A1 (es) Hidratos y polimorfos de 4-(((7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil)amino)-3- metoxi-n-(1-metil-4-piperidinil)-benzamida, procedimiento para su preparacion y su uso como farmaco
PE20081350A1 (es) Sal fumarato de (alfas s, beta r)-6-bromo-alfa-[2(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
BRPI0514750A (pt) derivados amida de 7-amino-3-fenil-diidropirimido[4, 5-d]pirimidinonas, sua fabricação e uso como inibidores de proteìna cinase
CY1112911T1 (el) Θεραπευτικος παραγοντας ηπατικης νοσου, που περιεχει παραγωγο 2-αμινο-1,3-προπανοδιολης ως δραστικο συστατικο
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
TW200643013A (en) Pyrazoles
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
CO5680425A2 (es) Formulaciones liofilizadas de cci-779
AR051754A1 (es) Metodos para preparar compuestos de indazol
DOP2006000243A (es) Derivados de pirazina
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
AR029412A1 (es) Forma cristalina
UY27979A1 (es) Indoles sustituidos en posición 2,4
UY30788A1 (es) Compuestos quimicos
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
NO20082181L (no) Formuleringer av Fispemifen
NI200700175A (es) Procesos para la preparación de alcoholes de aminoetoxibencilo
EA200801875A1 (ru) Антагонист cd 80
PE20060678A1 (es) Formas cristalinas de derivados de etilamina y procedimiento de preparacion de los mismos
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]